HIF-1 alpha gene therapy - Sanofi Genzyme

Drug Profile

HIF-1 alpha gene therapy - Sanofi Genzyme

Alternative Names: Ad2/HIF-1 alpha; Ad2/HIF-1a; Ad2/HIF-1α/VP16; Cardiovascular disease gene therapy - Sanofi Genzyme

Latest Information Update: 21 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Johns Hopkins University
  • Developer Genzyme Corporation
  • Class Gene therapies; Peripheral vasodilators
  • Mechanism of Action Angiogenesis inducing agents; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Intermittent claudication; Peripheral arterial disorders
  • Discontinued Ischaemic heart disorders

Most Recent Events

  • 31 Mar 2012 No development reported - Phase-II for Intermittent claudication in European Union (IM)
  • 31 Mar 2012 No development reported - Phase-II for Intermittent claudication in USA (IM)
  • 31 Mar 2012 No development reported - Phase-II for Peripheral arterial disorders in European Union (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top